Details of the Drug Reposition

General Information of This Drug (ID: DMVJNFI)

Drug Name
Spermidine   DMVJNFI
Synonyms
Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plaque psoriasis DISQX1LF EA90.0 Phase 3 [1]
Rheumatoid arthritis DISTSB4J FA20 Phase 3 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)